Plain-English translation of NCT04291105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing Voyager VI, a new treatment made from a modified virus, combined with (an immunotherapy medication that helps your immune system fight cancer). The virus-based medication is injected directly into tumors, while the immunotherapy is given through an IV. Researchers want to see if this combination works better than existing treatments for people with advanced melanoma, head and neck cancer, or colorectal cancer.
Many patients with these cancers have run out of standard treatment options or have tumors that have stopped responding to existing therapies. This new treatment uses an unusual approach—a virus designed to activate the immune system against cancer—hoping to offer hope to people for whom other treatments are no longer working.
If you enroll, you'll receive treatment every 3 weeks on an outpatient basis. Each treatment session involves an injection of the virus-based medication directly into your tumor, followed by an IV infusion of the immunotherapy medication. You'll return for check-up scans and evaluations every 6 weeks to see how your tumors are responding. You'll continue treatment until your cancer stops responding, side effects become too difficult to manage, or your doctor determines you're no longer benefiting—which could mean weeks to months of participation depending on how well the treatment works for you.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States